ANDA 207181, held by Regcon Holdings. Esomeprazole Sodium.
As of Nov 16, 2026, ANDA 207181 (Esomeprazole Sodium), held by Regcon Holdings, was first approved by FDA on Mar 6, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 6, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esomeprazole SodiumEQ 40MG BASE/VIAL ยท injectable;intravenous | Esomeprazole Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters